Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.95 USD

88.95
786,280

-0.05 (-0.06%)

Updated Oct 28, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

David Borun headshot

Markets Remain Calm But More Data and Earnings are Coming

by David Borun

Equities trend sideways as we wait for Congress and 30% of the S&P is set to report results.

Will Coronavirus Woes Impact Gilead's (GILD) Q2 Earnings?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports second-quarter 2020 results.

Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Earnings Preview: Gilead Sciences (GILD) Q2 Earnings Expected to Decline

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's (RHHBY) 1H20 Sales Hit by the Coronavirus Pandemic

by Zacks Equity Research

Roche's (RHHBY) performance in first-half 2020 was unimpressive as it bears the brunt of the COVID-19 outbreak.

Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker

by Zacks Equity Research

Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $78.08, moving +0.74% from the previous trading session.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation

by Zacks Equity Research

Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate

by Zacks Equity Research

Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.

Equillium Gains From Positive Results on Coronavirus Drug

by Zacks Equity Research

Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.

Ritujay Ghosh headshot

FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus

by Ritujay Ghosh

Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $76.68, moving +0.47% from the previous trading session.

Gilead Presents Additional Data on Coronavirus Drug Remdesivir

by Zacks Equity Research

Gilead (GILD) announces a comparative analysis of remdesivir, wherein the drug was associated with a 62% reduction in risk of mortality compared to standard of care.

Mark Vickery headshot

PepsiCo Beats in Q2, Disney World Reopens

by Mark Vickery

If Disney World reopens without creating a new disease hot spot, this may be a go-ahead sign for other entertainment facilities in other heavily affected regions of the U.S.

Q2 Earnings Season Kicks Off

by Zacks Equity Research

Q2 Earnings Season Kicks Off

Stock Market News for Jul 13, 2020

by Zacks Equity Research

Benchmarks ended higher on Friday as investors cheered positive results from Gilead's coronavirus vaccine candidate, remdesivir's clinical trial data, overlooking spike in new cases.

June PPI Drops Unexpectedly

by Zacks Equity Research

June PPI Drops Unexpectedly.

Fate's IND Application for CAR T Cell Therapy Gets FDA Nod

by Zacks Equity Research

Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.

    Mark Vickery headshot

    June PPI Weak at -0.2%, COVID Drug Adds Promise

    by Mark Vickery

    June Producer Price Index headline of -0.2% was a big miss from the +0.4% consensus and the +0.4% headline for May.

    Gilead Starts Testing Remdesivir Inhaled Version for Coronavirus

    by Zacks Equity Research

    Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.

    Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More

    by Zacks Equity Research

    The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

    Regeneron Initiates Studies on Experimental Coronavirus Drug

    by Zacks Equity Research

    Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

    Gilead Sciences (GILD) Stock Moves -0.44%: What You Should Know

    by Zacks Equity Research

    Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.

    Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis

    by Zacks Equity Research

    Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.